
Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.
ZMYM3 (zinc finger MYM-type containing 3) encodes a zinc finger-containing nuclear protein that participates in histone deacetylase-associated multiprotein complexes. Through these complexes, ZMYM3 contributes to chromatin modification and transcriptional repression. It therefore functions in regulation of gene expression through chromatin-dependent mechanisms.
143B is a human osteosarcoma cell line derived indirectly from the HOS osteosarcoma cell line. The cells are deficient in thymidine kinase (TK−) and resistant to bromodeoxyuridine (BUdR). 143B is used as a model for studying osteosarcoma biology, tumor metabolism, and genetic selection systems involving thymidine kinase deficiency.
Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 2
Reference Transcript: NM_001171162
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use






Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?